C3h mice

Eight week old female BALB/c and C3H mice were purchased from Taconic (New York, NY, USA). Tumor efficacy studies were conducted in three different syngeneic mouse models, namely colon carcinoma (CT26), bladder (MBT2) and B cell lymphoma (A20). For CT26 and A20 models, BALB/c mice were inoculated subcutaneously into the right lower flank with 1 × 10⁶ cells. For MBT2 experiments, C3H mice were injected with 1 × 10⁶ cells (lower right flank). Tumors were measured with calibers two times per week and tumor volumes determined using the relationship: (volume (mm³) = length × width²/2). Mice were euthanized when tumors reached a volume of 2000 mm³. Randomization of mice to treatment groups occurred when mean tumor volumes reached approximately 100 mm³. We examined increasing dose levels of CC1 (10 and 30 mg/kg; IP, QD every other day) on tumor growth in the CT26 model. Additionally we studied the effect of anti-CEACAM1 treatment alone (CC1 30 mg/kg; IP, QD every two days) and in combination with muDX400 (5 mg/kg; which is a murinized version of surrogate anti-mouse PD1 mAb.; QD every 5 days) in the CT26, MBT2 and A20 models. Vehicle controls received mouse IgG1 antibody and vehicle. The dose of muDX400 was chosen based on demonstrated efficacies achieved in syngeneic mouse tumor models [25 (link)].